The NRF2-p21-p53 signaling pathway plays a critical role in cancer drug resistance by enhancing cell survival mechanisms and promoting drug efflux, ultimately reducing the efficacy of anticancer therapies. This evidence concerns the gene CDKN1A and cancer.